Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 18/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386490 | 1.00 | CETP (0.42) | CETP | |
| SCHEMBL13837709 | 0.94 | CETP (0.39) | CETP | |
| SCHEMBL1900758 | 0.94 | CETP (0.39) | CETP | |
| SCHEMBL6280371 | 0.94 | CETP (0.43) | CETP | |
| SCHEMBL992083 | 0.94 | CETP (0.43) | CETP | |
| SCHEMBL6277527 | 0.93 | CETP (0.39) | CETP | |
| SCHEMBL1903178 | 0.93 | CETP (0.39) | CETP | |
| SCHEMBL5671544 | 0.92 | CETP (0.43) | CETP | |
| SCHEMBL6064717 | 0.92 | CETP (0.42) | CETP | |
| SCHEMBL6231524 | 0.92 | CETP (0.42) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-2305217-B1 | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | BEND RES INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2305217-A1 | Method for the preparation of pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | Bend Research, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-1404302-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ADSORBATES OF AMORPHOUS DRUG | PFIZER PROD INC (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1399190-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | BEND RES INC (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-1961419-B1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER PROD INC (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1961419-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | Pfizer Products Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1581210-B1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PROD INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7235259-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| US-20030186952-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030170309-A1 | Pharmaceutical compositions containing polymer and drug assemblies | BABCOCK WALTER C (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003063868-A1 | CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003000226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170309-A1 | Pharmaceutical compositions containing polymer and drug assemblies | PRNP, PUF60, ABCB1 | CETP 315/4885 |
| US-20030186952-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.